Indoramin

{{Drugbox | Verifiedfields = changed | verifiedrevid = 461936008 | IUPAC_name = N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzamide | image = Indoramin_svg.png

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^N | CAS_number = 26844-12-2 | ATC_prefix = C02 | ATC_suffix = CA02 | PubChem = 33625 | IUPHAR_ligand = 501 | DrugBank_Ref =  ^Y | DrugBank = | ChemSpiderID_Ref =  ^Y | ChemSpiderID = 31014 | UNII_Ref =  ^Y | UNII = 0Z802HMY7H | KEGG_Ref =  ^Y | KEGG = D04531 | ChEMBL_Ref =  ^Y | ChEMBL = 279516

| C=22 | H=25 | N=3 | O=1 | molecular_weight = 347.454 g/mol | smiles = O=C(c1ccccc1)NC4CCN(CCc3c2ccccc2nc3)CC4 | InChI = 1/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) | InChIKey = JXZZEXZZKAWDSP-UHFFFAOYAC | StdInChI_Ref =  ^Y | StdInChI = 1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) | StdInChIKey_Ref =  ^Y | StdInChIKey = JXZZEXZZKAWDSP-UHFFFAOYSA-N }}

WikiDoc Resources for Indoramin
Articles
Most recent articles on Indoramin Most cited articles on Indoramin Review articles on Indoramin Articles on Indoramin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Indoramin Images of Indoramin Photos of Indoramin Podcasts & MP3s on Indoramin Videos on Indoramin
Evidence Based Medicine
Cochrane Collaboration on Indoramin Bandolier on Indoramin TRIP on Indoramin
Clinical Trials
Ongoing Trials on Indoramin at Clinical Trials.gov Trial results on Indoramin Clinical Trials on Indoramin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Indoramin NICE Guidance on Indoramin NHS PRODIGY Guidance FDA on Indoramin CDC on Indoramin
Books
Books on Indoramin
News
Indoramin in the news Be alerted to news on Indoramin News trends on Indoramin
Commentary
Blogs on Indoramin
Definitions
Definitions of Indoramin
Patient Resources / Community
Patient resources on Indoramin Discussion groups on Indoramin Patient Handouts on Indoramin Directions to Hospitals Treating Indoramin Risk calculators and risk factors for Indoramin
Healthcare Provider Resources
Symptoms of Indoramin Causes & Risk Factors for Indoramin Diagnostic studies for Indoramin Treatment of Indoramin
Continuing Medical Education (CME)
CME Programs on Indoramin
International
Indoramin en Espanol Indoramin en Francais
Business
Indoramin in the Marketplace Patents on Indoramin
Experimental / Informatics
List of terms related to Indoramin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.

It is an alpha-1 selective adrenoceptor antagonist with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).

It is commonly synthesized from tryptophol.

Dosage

Indoramin is commonly prescribed as 20mg tablets when used in BPH.

Side Effects

Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.